Engineered immune cells take aim at stubborn leukemia
NCT ID NCT05672147
Summary
This early-stage study is testing a new type of personalized cell therapy for adults with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatments. Doctors take immune cells from a donor, genetically modify them in a lab to better recognize and attack the patient's leukemia cells, and then infuse them back into the patient. The main goals are to find a safe dose and see what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.